news
Novel cancer therapeutic synthesised by Stanford researchers
The natural compound tigilanol tiglate was produced in a lab for the first time by scientists at Stanford University, suggesting it could provide treatment for a variety of cancers.
List view / Grid view
Head and Neck Cancer
article
Advancing cell therapies – γδ T cells and the combination factor
In this Q&A, Bryan Kobel, Chief Executive Officer of TC Biopharm, discusses innovations in cell therapies, introducing the company’s work in gamma delta (γδ) T-cell technologies and his predictions for the future of cell therapy development.
news
Rise of biologics set to continue, says report
According to a new report, biologics are forecast to have $120 billion greater sales than small molecules by 2027.
article
COVID’s impact on cancer therapeutics: clinical trial and treatment disruptions
In this article, European Pharmaceutical Review’s Hannah Balfour discusses how COVID-19 has impacted the pharma industry with regard to cancer clinical trial and treatment disruptions.
news
Nanoparticle drug delivery could be the future of targeted cancer therapies
Researchers have created targeted, modifiable nanoparticles which could be combined with pharmaceuticals as a form of drug delivery to treat cancer.
news
NICE requests more data on Keytruda for head and neck cancer treatment
NICE has asked for more information on Keytruda (pembrolizumab) for untreated metastatic or unresectable recurrent squamous cell head and neck cancer due to uncertainty over clinical trial evidence.
news
Immunotherapy for metastatic or recurrent head and neck cancer
The KEYNOTE-048 study examined the use of immunotherapy with pembrolizumab rather than the standard treatment using cetuximab for head and neck cancer...
news
TLR agonists suppress tumour growth
TLR agonists injected directly into a tumour suppresses tumour growth throughout the whole body...
news
Head and neck cancer market fertile for investment
8 March 2017 | By GBI Research
A substantial number of first-in-class products in the head and neck cancer pipeline will reach the market over the coming decade, which could potentially transform the clinical and commercial landscape, according to business intelligence firm GBI Research.
news
NICE says head and neck cancer drug cetuximab is not cost-effective
7 November 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE was reconsidering cetuximab as part of its programme to appraise drugs that are currently available on the Cancer Drugs Fund...
news
‘Game-changing’ immunotherapy doubles head and neck cancer survival
10 October 2016 | By Niamh Louise Marriott, Digital Content Producer
An immunotherapy drug has been hailed as a ‘game changer’ after being found to greatly improve survival for patients with relapsed head and neck cancer...
news
First patient recruited in Visco-ease RIX study
29 March 2016 | By Victoria White
The study will assess Visco-ease’s ability to restore the function of saliva in patients undergoing radiotherapy for the treatment of Head and Neck Cancer...
